The Language of Life Sciences Trade

In the corridors of US-LATAM and US-Africa trade, healthcare and life sciences represent a rapidly expanding frontier—driven by demographic shifts, rising chronic disease burdens, and the push for local manufacturing capacity. Whether you are navigating FDA-equivalent approvals in Mexico (COFEPRIS), Brazil (ANVISA), or South Africa (SAHPRA), or structuring distribution agreements for medical devices and biologics, the vocabulary of this sector is both technical and commercially charged. This glossary defines the essential terms that cross borders, contracts, and customs, giving you a practical reference for negotiating, complying, and scaling in these high-growth markets.

Regulatory & Approval Terms

ANVISA (Agência Nacional de Vigilância Sanitária) — Brazil’s national health surveillance agency, equivalent to the US FDA. ANVISA registration is mandatory for all medical products sold in Brazil, and its approval timelines can significantly impact market entry strategies for US exporters. (Portuguese: ANVISA)

COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) — Mexico’s federal commission for protection against health risks, responsible for regulating pharmaceuticals, medical devices, and biologics. COFEPRIS authorization is a prerequisite for commercializing any healthcare product in Mexico. (Spanish: COFEPRIS)

SAHPRA (South African Health Products Regulatory Authority) — South Africa’s medicines and medical devices regulator, which oversees clinical trials, product registration, and post-market surveillance. SAHPRA approval is often a gateway for broader Southern African distribution. (English: SAHPRA)

510(k) Premarket Notification — A submission made to the US FDA to demonstrate that a medical device is substantially equivalent to a legally marketed predicate device. For LATAM and African importers, a 510(k) clearance often simplifies local registration pathways under mutual recognition agreements. (English: 510(k))

Marketing Authorization (MA) — The official approval granted by a national regulatory authority to place a pharmaceutical or medical device on the market. In LATAM, MA processes vary by country—some accept FDA or EMA approvals as a basis for accelerated review. (Spanish: Autorización de Comercialización; Portuguese: Autorização de Comercialização)

Supply Chain & Distribution Terms

Cold Chain — The temperature-controlled supply chain required for vaccines, biologics, and certain pharmaceuticals. Maintaining cold chain integrity from US manufacturing sites to distribution hubs in Lagos, São Paulo, or Nairobi is critical and often involves specialized logistics partners. (Spanish: Cadena de Frío; Portuguese: Cadeia de Frio)

Good Distribution Practices (GDP) — Quality assurance standards for the storage and transportation of pharmaceutical products. GDP compliance is a legal requirement in most LATAM and African markets, and audits are increasingly common at border inspection points. (Spanish: Buenas Prácticas de Distribución; Portuguese: Boas Práticas de Distribuição)

Incoterms (e.g., CIF, FOB) — International commercial terms that define the responsibilities of buyers and sellers in cross-border transactions. For healthcare shipments, CIF (Cost, Insurance, Freight) is common for high-value biologics, while FOB (Free on Board) is often used for bulk raw materials. (English: Incoterms)

Letter of Credit (LC) in Healthcare Trade — A bank-issued guarantee of payment used in large-value pharmaceutical and medical device transactions. LCs mitigate risk when dealing with new distributors in LATAM or Africa, where payment terms can be extended. (Spanish: Carta de Crédito; Portuguese: Carta de Crédito)

Commercial & Reimbursement Terms

Health Technology Assessment (HTA) — A systematic evaluation of the clinical and economic value of a health technology, often required for reimbursement decisions in public healthcare systems. In countries like Brazil and South Africa, HTA outcomes directly influence pricing and market access. (English: HTA)

Reference Pricing — A strategy where a product’s price is set based on the price of similar products in a basket of reference countries. US exporters to LATAM often face reference pricing from Mexico, Colombia, or Chile, which can compress margins. (Spanish: Precio de Referencia; Portuguese: Preço de Referência)

Reimbursement Code (e.g., CPT, HCPCS) — Standardized codes used to bill for medical procedures and devices. Without the correct local reimbursement code in markets like Mexico or South Africa, a product may be effectively excluded from hospital formularies. (English: Reimbursement Code)

Formulary — A list of medicines and devices approved for use within a hospital, health system, or insurance plan. Inclusion in a public hospital formulary in Kenya or Brazil can drive volume but often requires price negotiations and clinical evidence. (Spanish: Formulario; Portuguese: Formulário)

Intellectual Property & Licensing Terms

Patent Term Extension (PTE) — Additional patent protection granted to compensate for regulatory approval delays. In LATAM, PTE rules vary—Mexico offers up to five years, while Brazil has historically been more restrictive—impacting market exclusivity for US innovators. (Spanish: Extensión de Plazo de Patente; Portuguese: Extensão de Prazo de Patente)

Compulsory License — A government-authorized license allowing a third party to produce a patented product without the patent holder’s consent, typically for public health reasons. Countries like South Africa have used compulsory licensing for HIV/AIDS drugs, a risk factor for US pharma exporters. (Spanish: Licencia Obligatoria; Portuguese: Licença Compulsória)

Data Exclusivity — A period during which a regulatory authority cannot rely on the clinical trial data submitted by an innovator to approve a generic competitor. Data exclusivity periods in LATAM range from five to ten years, affecting the timing of generic entry. (Spanish: Exclusividad de Datos; Portuguese: Exclusividade de Dados)

Technology Transfer Agreement — A contract under which a US company shares manufacturing know-how, processes, or cell lines with a partner in LATAM or Africa, often as part of a local production initiative. These agreements are central to biosimilar and vaccine manufacturing partnerships. (Spanish: Acuerdo de Transferencia de Tecnología; Portuguese: Acordo de Transferência de Tecnologia)

Clinical & Quality Terms

Good Manufacturing Practice (GMP) — Quality standards for the manufacturing of pharmaceuticals and medical devices. GMP certification by a recognized authority (e.g., US FDA, WHO) is often a prerequisite for export to LATAM and Africa, where local inspections may be less frequent. (Spanish: Buenas Prácticas de Fabricación; Portuguese: Boas Práticas de Fabricação)

Biosimilar — A biological product that is highly similar to an already approved reference biologic, with no clinically meaningful differences. Biosimilar adoption is growing in LATAM and Africa as cost-saving alternatives, but regulatory pathways vary significantly. (Spanish: Biosimilar; Portuguese: Biossimilar)

Clinical Trial Authorization (CTA) — Approval from a national regulatory authority and ethics committee to conduct a clinical trial. For US sponsors running trials in South Africa or Brazil, CTA timelines and local content requirements (e.g., inclusion of local populations) are key planning factors. (Spanish: Autorización de Ensayo Clínico; Portuguese: Autorização de Ensaio Clínico)

Pharmacovigilance (PV) — The science of monitoring the safety of medicines after they reach the market. LATAM and African regulators increasingly require local PV systems and periodic safety reports, adding compliance costs for foreign manufacturers. (Spanish: Farmacovigilancia; Portuguese: Farmacovigilância)

At Coppermont, we apply these terms daily to structure cross-border healthcare transactions—from negotiating distribution agreements with cold chain logistics clauses to advising on regulatory strategy for biosimilar market entry in Brazil and Angola. Our team combines legal, commercial, and regulatory expertise to help you move products from US labs to patient bedsides across LATAM and Africa.

Ready to navigate healthcare trade in LATAM or Africa?
Schedule a consultation with Coppermont’s Healthcare & Life Sciences advisory team.